{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:59:46Z","timestamp":1780451986247,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"am","delay-in-days":259,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21am0101089"],"award-info":[{"award-number":["JP21am0101089"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21am0101124"],"award-info":[{"award-number":["JP21am0101124"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001697","name":"Keio University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001697","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.dmpk.2021.100439","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T05:40:41Z","timestamp":1639633241000},"page":"100439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Synthesis and evaluation of tofacitinib analogs designed to mitigate metabolic activation"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1884-014X","authenticated-orcid":false,"given":"Yasuhiro","family":"Tateishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Shibazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1508-3430","authenticated-orcid":false,"given":"Kyoko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9681-3510","authenticated-orcid":false,"given":"Shigeo","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kazuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiko","family":"Mashino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5646","key":"10.1016\/j.dmpk.2021.100439_bib1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.dmpk.2021.100439_bib2","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/jm1004286","article-title":"Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection","volume":"53","author":"Flanagan","year":"2010","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.dmpk.2021.100439_bib3","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with Covid-19 pneumonia","volume":"385","author":"Guimaraes","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.dmpk.2021.100439_bib4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s11926-009-0054-9","article-title":"Intracellular signal pathways: potential for therapies","volume":"11","author":"Mavers","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.dmpk.2021.100439_bib5","first-page":"41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J\u00a0Inflamm"},{"issue":"8","key":"10.1016\/j.dmpk.2021.100439_bib6","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.dmpk.2021.100439_bib7","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.dmpk.2021.100439_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.pharmtox.47.120505.105150","article-title":"Idiosyncratic drug reactions: current understanding","volume":"47","author":"Uetrecht","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"10.1016\/j.dmpk.2021.100439_bib9","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1021\/acs.chemrestox.9b00141","article-title":"Tofacitinib is a mechanism-based inactivator of cytochrome P450 3A4","volume":"32","author":"Guo","year":"2019","journal-title":"Chem Res Toxicol"},{"issue":"11","key":"10.1016\/j.dmpk.2021.100439_bib10","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1021\/tx200304r","article-title":"2,7-Disubstituted-pyrrolotriazine kinase inhibitors with an unusually high degree of reactive metabolite formation","volume":"24","author":"Wells-Knecht","year":"2011","journal-title":"Chem Res Toxicol"},{"issue":"23\u201324","key":"10.1016\/j.dmpk.2021.100439_bib11","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1016\/j.bmcl.2018.10.023","article-title":"Synthesis of novel benzbromarone derivatives designed to avoid metabolic activation","volume":"28","author":"Ohe","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"issue":"50","key":"10.1016\/j.dmpk.2021.100439_bib12","doi-asserted-by":"crossref","first-page":"32608","DOI":"10.1021\/acsomega.0c04942","article-title":"Development of novel diclofenac analogs designed to avoid metabolic activation and hepatocyte toxicity","volume":"5","author":"Tateishi","year":"2020","journal-title":"ACS Omega"},{"issue":"4","key":"10.1016\/j.dmpk.2021.100439_bib13","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jhet.2384","article-title":"An efficient method for synthesis of tofacitinib citrate","volume":"53","author":"Zhi","year":"2016","journal-title":"J\u00a0Heterocycl Chem"},{"issue":"12","key":"10.1016\/j.dmpk.2021.100439_bib14","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1021\/op500274j","article-title":"An improved and efficient process for the preparation of tofacitinib citrate","volume":"18","author":"Patil","year":"2014","journal-title":"Org Process Res Dev"},{"issue":"41","key":"10.1016\/j.dmpk.2021.100439_bib15","doi-asserted-by":"crossref","first-page":"13639","DOI":"10.1021\/ja803336y","article-title":"Fluorine substituted adenosines as probes of nucleobase protonation in functional RNAs","volume":"130","author":"Suydam","year":"2008","journal-title":"J\u00a0Am Chem Soc"},{"issue":"11","key":"10.1016\/j.dmpk.2021.100439_bib16","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1002\/cmdc.201402252","article-title":"Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres","volume":"9","author":"Gehringer","year":"2014","journal-title":"ChemMedChem"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100439_bib17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.dmpk.2020.01.006","article-title":"Synthesis and evaluation of nevirapine analogs to study the metabolic activation of nevirapine","volume":"35","author":"Tateishi","year":"2020","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"10","key":"10.1016\/j.dmpk.2021.100439_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187072","article-title":"Establishment of a novel hepatocyte model that expresses four cytochrome P450 genes stably via mammalian-derived artificial chromosome for pharmacokinetics and toxicity studies","volume":"12","author":"Satoh","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.dmpk.2021.100439_bib19","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2021.100439_bib20","doi-asserted-by":"crossref","first-page":"100386","DOI":"10.1016\/j.dmpk.2021.100386","article-title":"Development of fluorescent-labeled trapping reagents based on cysteine to detect soft and hard electrophilic reactive metabolites","volume":"39","author":"Shibazaki","year":"2021","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.dmpk.2021.100439_bib21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tox.2019.02.005","article-title":"Mechanisms of soft and hard electrophile toxicities","volume":"418","author":"LoPachin","year":"2019","journal-title":"Toxicology"},{"issue":"3","key":"10.1016\/j.dmpk.2021.100439_bib22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jmb.2010.05.020","article-title":"Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6","volume":"400","author":"Chrencik","year":"2010","journal-title":"J\u00a0Mol Biol"},{"issue":"8","key":"10.1016\/j.dmpk.2021.100439_bib23","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1124\/dmd.31.8.1035","article-title":"Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties","volume":"31","author":"Wilkening","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2021.100439_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10565-011-9208-4","article-title":"Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins","volume":"28","author":"Gerets","year":"2012","journal-title":"Cell Biol Toxicol"},{"issue":"10","key":"10.1016\/j.dmpk.2021.100439_bib25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd3801","article-title":"The determination and interpretation of the therapeutic index in drug development","volume":"11","author":"Muller","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.dmpk.2021.100439_bib26","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrd2378","article-title":"The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates","volume":"6","author":"Kramer","year":"2007","journal-title":"Nat Rev Drug Discov"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436721000604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436721000604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:56:30Z","timestamp":1761162990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436721000604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":26,"alternative-id":["S1347436721000604"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2021.100439","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of tofacitinib analogs designed to mitigate metabolic activation","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2021.100439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100439"}}